Analysts’ Recommendations for AbbVie in January

On January 10, AbbVie (ABBV) closed at $88.20, 0.44% higher than its previous closing price. The company closed at a premium of 13.81% to its 52-week low price of $77.50 and a discount of 29.92% to its 52-week high price of $125.86. On January 10, AbbVie’s market cap was $132.91 billion. The company was trading at a trailing PE ratio of 17.37x and a forward PE ratio of 10.12x.

Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter. AbbVie had also reported returns of -7.12% in the last half year, -12.01% in the last year, and -4.33% YTD (year-to-date).

Based on its closing price on January 10, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 4.85% in the last week, -3.73% in the last month, and -7.30% in the last quarter. XLV had also reported returns of 1.44% in the last half year, 1.84% in the last year, and 1.17% YTD.

AbbVie has been mostly underperforming the broader healthcare sector represented by XLV in 2018 and 2019.

The 12-month consensus analyst recommendation for AbbVie on January 11 was a “hold.” The 12-month consensus target price for the company was $99.28, 12.56% higher than its closing price on January 10. The highest target price estimate for the company was $135, and the lowest target price estimate was $71.

Of the 19 analysts covering AbbVie on January 10, three analysts rated the company as a “strong buy,” four analysts rated it as a “buy,” nine rated it as a “hold,” two rated it as a “sell,” and one rated it as a “strong sell.”

In the next article, we’ll compare the revenue growth prospects of Merck & Co. (MRK) and AbbVie in greater detail.